F9 and hemophilia B: A recent clinical trial using i.v. administrations of AAV2/8 in patients with hemophilia B proved the safety and efficacy of AAV2/8 liver gene transfer,25 resulting in long-term expression of factor IX (FIX) at therapeutic levels.26,27